At the surface, the immune response to a flu virus is simple. Some cells recognize the pathogen and send a signal to the ...

Antibody Solutions, a leading provider of fit-for-purpose antibody discovery services, announced today that for the first time, single plasma B-cell discovery services will be part of the company ...

T-bet is a transcription factor, one of the control proteins in the cell nucleus that can turn specific groups of genes on ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

In a significant step toward improving targeted cancer therapy, researchers from Japan have developed a novel nanocarrier ...

Circulate Health, a Seattle health longevity startup, today announced $12 million in seed funding to expand its plasma ...

Now, scientists say the woman is the only known carrier of a new blood type called “Gwada negative.” It’s the only blood type within a new blood group system that scientists have dubbed “PigZ,” which ...

A "Trojan horse" therapy that sneaks toxic drugs inside cancer cells is being made available on the NHS in England in a world first. It can halt the blood cancer myeloma for nearly three times longer ...

Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab-gcpt) has been granted accelerated approval by the US Food and Drug ...

Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...

According to Regeneron, the drug is a bispecific antibody that binds to B-cell maturation antigen (BCMA) on cancerous plasma cells and CD3 on T cells, directing the immune system to attack and destroy ...

The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous ...